Author Index

Abraham HD, 28
Adair D, 12
Adams BM, 162
Amend D, 16
Applegate MD, 125

Baker FM, 65
Baker RW, 12
Barnhart RL, 203
Beatty WW, 132
Beck BJ, 189
Bell IR, 16
Benes C, 226
Bharwani I, 159
Bianchetti A, 42
Bliwise DL, 107
Borson S, 203
Bowen JD, 154
Brannigan GG, 209
Brookmeyer R, 238

Chengappa KNR, 12
Cheong JA, 1
Chiu HFK, 49
Cohen MS, 177
Cohen RA, 217
Cohen-Mansfield J, 52
Cornell J, 4
Corrada M, 238
Coyne AC, 96
Cremens MC, 77, 138, 200, 244
Cutler NR, 226

Drachman DA, 32, 217

Edland SD, 203
Ellias SA, 71

Fakouhi TD, 226
Farber NJ, 141
Freilicher J, 173
Frisoni GB, 42

Geroldi C, 42
Glatt SL, 38, 184
Grossberg GT, 168

Hafner RJ, 213
Halperin P, 28
Hamos JE, 32
Hantsburger G, 226
Hedreen JC, 125
Hershey LA, 231
Herting R, 226
Hodder RA, 177
Holme G, 213
Holroyd S, 118
Houx PJ, 111
Hubble JP, 38, 184
Hughes J, 154
Hughes M, 107
Huszonek JJ, 100

Irbe D, 107

Jenike MA, 76, 79, 137, 197, 243
Jhee SS, 226
Jolles J, 23, 111

Karagiozis H, 238
Kaszniak AW, 16
Kawas C, 238
Kelsey MC, 168
Kemp BJ, 162
Kim KY, 123
Koller WC, 38, 184
Kreinbrook SB, 12
Kukull W, 203
Kunik ME, 234
Kuzma MA, 141

Lannon MC, 71
Larson EB, 154, 203
Leipsic JS, 28
Leo RJ, 123, 231
Lichter DG, 231
Lippa CF, 32
Lish JD, 141
Little JT, 103
Lloyd C, 213
Lush D, 141

Mahurin RK, 4
Marmion J, 61
McCaffrey N, 209
McGowan J, 209
McLean P, 203
Meadows M-E, 217

Miller FT, 173
Miller JW, 16
Molinari V, 61
Moonis M, 217

Nadler JD, 177

O'Donnell BF, 217
Ogunniyi A, 65
O'Keeffe ST, 120
Osuntokun BO, 65
Ott BR, 71

Paolo AM, 38, 184
Paskavitz JF, 32
Patel SV, 81
Penetrante AE, 159
Peterson JM, 16
Pizzolato G, 42
Plescia G, 141
Plum F, 177
Ponds RWHM, 23
Price DL, 125
Prince JR, 132
Pulaski-Salo D, 32
Puryear LJ, 234

Raheja RK, 159
Raskin LS, 125
Raskind M, 203
Reichman WE, 96
Reingold J, 177
Relkin NR, 177
Resau L, 238
Rossato A, 42
Royall DR, 4
Rozendaal N, 23
Ryan GT, 209
Ryan JP, 209
Rye DB, 107

Samander J, 1
Satlin A, 103
Schwartz GE, 16
Schwartz P, 226
Scott JG, 132
Selhub J, 16
Smith D, 118
Snowden MB, 154
Sramek JJ, 226
Stini WA, 16
Stone WF, 217
Sunderland T, 103
Swabb EA, 226

Teri L, 203
Trabucchi M, 42
Troncoso JC, 125
Trîster AI, 38, 184
Tueth MJ, 1

van Belle G, 203
Verhey FRJ, 23, 111
Volicer L, 103
Vreeling FW, 111

Watts N, 107
Watts RL, 107
Williamson DJ, 132
Wilson DA, 132
Workman R, Jr., 234

Zandi T, 209
Zimmerman M, 141

Subject Index

Affective disorders, 61–63
Agitation, 52–59, 246
Agitation Behavior Mapping Instrument, 57
Alzheimer's disease, 4–9, 23–26, 32–36, 38–41, 71–75, 81–90, 96–99, 103–105, 107–110, 111–116, 125–130, 132–136, 191, 209–212, 226–229, 246–247, 248
Alzheimer's Disease Patient Registry, 203–207
Alzheimer's Disease Research Center Registry, 203–207
Aminergic drugs, 86
Amnesia, 132–136
Anterograde memory, 132–136
Antiamyloid strategies, 88
Anticholinergics, 100–102
Anti-infective strategies, 89
Antitoxic therapies, 89
Anxiety disorders, 142
Axis II diagnoses, 61–63

Behavioral disorders, 159–161, 213–216, 247–248
Bender Visual Motor Gestalt Test, 209–212
Benztropine, 100–102
Bereavement, 245–246
Blessed Dementia Scale, 23–26
Blessed Information Memory Concentration Test, 213–216, 238–241
Bradykinesia, 71–75
Brief Psychiatric Rating Scale, 234–237

Caffeine–augmented ECT, 168–172
Carbamazepine, 246
Catecholaminergic drugs, 85–86
Charles Bonnet syndrome, 1–3
Cholinergic drugs, 82
Cimetidine, 231–232
Clock Drawing Test, 209–212
Clomipramine, 123–124
Clozapine, 12–15, 247–248
Cognitive Drug Research Test, 226–229
Cognitive function, 81–90
Cohen-Mansfield Agitation Inventory, 55–56, 234–237
Corticobasal degeneration, 132–136
Cycloserine, 226–229

Delirium, 120–122, 245
Delusions of infestation, 120–122
Delusions of jealousy, 49–51
Dementia, 4–9, 23–26, 65–69, 103–105, 123–124, 132–136, 213–216, 217–225, 246
Dementia of Alzheimer's type, 81–90, 154–158, 184–187, 244
Dementia of frontal type, 42–47
Dementia Rating Scale, 38–41, 154–158, 184–187
Depression, 4–9, 23–26, 96–99, 100–102, 141–151, 173–176, 197–199, 231–232, 244–245, 246–247, 248
Diffuse Lewy body disease, 189–194
Disruptive behavior, 52–59, 103–105, 107–110
Dorsomedial nucleus, 32–36
Drugs, 81–90
Dysthymia, 246–247, 248

Eating disorders, 142–143
Electroconvulsive therapy, 168–172
Event-related potentials, 217–225
Executive Interview, 4–9

Famous Faces Test, 132–136
Fluoxetine, 100–102, 231–232
Frailty, 76
Frontal lobe dysfunction, 244–245
Fun-induced headache, 243

Hallucinations, 1–3
Haloperidol, 244
Headache, 243
Hong Kong Chinese, 49–51

Infestation, 120–122
Insight, 23–26

Jealousy, 49–51

Lewy bodies, 189–194
Lithium, 118–119

Magnetic resonance imaging, 132–136
Membrane modifying agents, 88
Memory deficits, 132–136
Mental status testing, 177–182
Metabolic enhancers, 87–88
Mini-Mental State Examination, 38–41,103–105, 132–136, 154–158, 177–182, 213–216, 234–237
Multi-infarct dementia, 96–99

Neurofibrillary tangles, 32–36, 125–130
Neuroleptic malignant syndrome, 28–30
Neurotransmitters, 82–87
Neurotrophic factors, 87
Nigerian patients, 65–69
Nocturnal disruptive behavior, 103–105, 107–110
Nondepressive disorders, 143, 145–147
Nursing homes, 177–182

Older Adult Health and Mood Questionnaire, 162–167

Paraphilias, 123–124
Parkinsonism, 118–119, 154–158, 231–232
Parkinson's disease, 16–20, 38–41, 100–102, 107–110, 133, 184–187
Peptidergic therapies, 86–87
Perseveration, 209–212
Personality changes, 23–26
Personality disorders, 61–63
Pick bodies, 189–194
Positron emission tomography, 132
Post-traumatic stress disorder, 137
Primitive reflexes, 111–116
Psychiatric patients, 234–237
Psychoses, 12–15, 247–248

Qualitative Evaluation of Dementia, 4–9

Rating Scale for Side Effects, 234–237
Receptor agonists, 84–85
Reflexes, 111–116
Remote memory, 132–136
Restless legs syndrome, 120–122
Retrograde memory, 132–136
Risperidone, 159–161

Screening, 141–151
Selective serotonin reuptake inhibitors, 173–176, 231–232
Senile plaques, 32–36, 125–130
Serotonergic drugs, 86
Serotonin reuptake inhibitors, 173–176, 231–232
Sexually inappropriate conduct, 123–124
Shyness, 16–20
Single photon emission tomography, 42–47
Slow-moving elderly, 76
Somatization disorders, 244
Stockton Geriatric Rating Scale, 213–216
Structured Interview for Disorders of Personality, 61–63
Substance abuse disorders, 142
Sundown syndrome, 103–105, 107–110

Thalamus, 32–36
Trait shyness, 16–20
Tricyclic antidepressants, 173–176

Vascular agents, 89
Vascular dementia, 23–26, 111–116

Wechsler Adult Intelligence Scale, 38–41, 133–134
Women, 12–15